Registered Nurse in Audubon, NJ Accepting Medicare
4 Registered Nurse nurses found. Showing 1 - 4
 Jeffrey Rowse, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 509 Cedarcroft Ave, Audubon, NJ 08106 Phone: 800-950-6066 |
 Sandra L Mayer, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 230 Oakland Ave, Apartment 6, Audubon, NJ 08106 Phone: 732-586-1078 Fax: 609-588-2950 |
Rachel Marie Sharpley, RN Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 719 Willitts Ave, Audubon, NJ 08106 Phone: 609-440-6275 |
Melanie N Hurst, F.N.P.C. Registered Nurse Medicare: Accepting Medicare Assignments Practice Location: 41 E Kings Hwy, Audubon, NJ 08106 Phone: 888-982-8594 Fax: 888-982-8594 |
News Archive
Cancer cell resistance to chemotherapy drugs - mechanism discovered
Technion-Israel Institute of Technology researchers have discovered new mechanisms developed by cancer cells to become resistant to various chemotherapy drugs.
GOP governors say health 'deals' are being cut without their input
"Twenty Republican governors and governors-elect are accusing the White House of providing too little transparency on health care, causing worry that 'deals' are being cut without their input," Politico reports. "In a letter sent Wednesday to the Congressional leaders of both parties, the governors wrote that they are 'disappointed with the lack of transparency' as health care moves forward. … The letter comes, in part, as a response to the Obama administration's move to bring in Democratic governors to stump for the bill ahead of its expected passage" (Barr, 1/14).
Study looks at role of race, gender in predicting heart attack symptoms in emergency department
Researchers at the George Washington University found that certain symptoms are more and less predictive of patients' risk for acute coronary syndrome, which includes heart attack, in patients of different gender and race.
AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer
The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners.
FDA grants final approval to Breckenridge's Pioglitazone Hydrochloride ANDA
Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Pioglitazone Hydrochloride Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Synthon Pharmaceuticals, Inc., and will be available in 15 mg, 30 mg, and 45 mg strengths.
› Verified 6 days ago